Market capitalization | SEK30.95b |
Enterprise Value | SEK32.08b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 45.83 |
EV/Sales (TTM) EV/Sales | 9.03 |
P/S ratio (TTM) P/S ratio | 8.71 |
P/B ratio (TTM) P/B ratio | 2.36 |
Dividend yield | 0.44% |
Last dividend (FY23) | SEK1.00 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a Vitrolife forecast:
3 Analysts have issued a Vitrolife forecast:
Sep '24 |
+/-
%
|
||
Revenue | 3,553 3,553 |
3%
3%
|
|
Gross Profit | 1,811 1,811 |
6%
6%
|
|
EBITDA | 1,221 1,221 |
5%
5%
|
EBIT (Operating Income) EBIT | 783 783 |
6%
6%
|
Net Profit | -3,805 -3,805 |
1,047%
1,047%
|
In millions SEK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vitrolife AB engages in the development, manufacture, and sale of products and systems for the preparation, cultivation, and storage of human cells, tissue, and organs. Its products and services include oocyte retrieval needles, sperm processing, IVF media and oil, micromanipulation pipettes, labware, benchtop incubators, time-lapse systems, preimplantation genetic testing, cryopreservation, laser and imaging systems, and lab quality control systems. The firm operates through the following geographical segments: Europe, Middle East, and Africa (EMEA); North and South America; Japan and Pacific; and Asia. The company was founded in 1994 and is headquartered in Gothenburg, Sweden.
Head office | Sweden |
CEO | Bronwyn Brophy |
Employees | 1,121 |
Founded | 1989 |
Website | www.vitrolife.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.